[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"area-therapeutic-list":3},["Reactive",4],[5,13,20,27],{"id":6,"therapeuticArea":7,"description":8,"introduction":9,"targets":10,"mice":11,"pic":12},2,"Oncology","Cancer remains one of the most complex and resource-intensive global health challenges. Biocytogen's antibody library delivers high-quality, experimentally validated human antibody sequences to enable rapid proof-of-concept for bispecifics, TCEs, and other next-generation therapies.","\u003Cp>Cancer remains one of the most complex and resource-intensive global health challenges. Biocytogen's antibody library delivers high-quality, experimentally validated human antibody sequences to enable rapid proof-of-concept for bispecifics, TCEs, and other next-generation therapies.\u003C\u002Fp>","ALPL,CDH6","RM,RL,RN","https:\u002F\u002Fbiocytogen-no2.oss-cn-beijing.aliyuncs.com\u002F20251204\u002Farea-top-img2_1764825154895.png",{"id":14,"therapeuticArea":15,"description":16,"introduction":17,"targets":10,"mice":18,"pic":19},3,"Inflammation & Autoimmunity","Autoimmune diseases affect millions worldwide and continue to rise. Biocytogen's million-scale human antibody library supports rapid screening of multi-mechanism antibodies, accelerating the development of bispecific, trispecific, and TCE therapies.","\u003Cp>Autoimmune diseases affect millions worldwide and continue to rise. Biocytogen's million-scale human antibody library supports rapid screening of multi-mechanism antibodies, accelerating the development of bispecific, trispecific, and TCE therapies.\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>","RN","https:\u002F\u002Fbiocytogen-no2.oss-cn-beijing.aliyuncs.com\u002F20251204\u002Farea-top-img3_1764825905337.png",{"id":21,"therapeuticArea":22,"description":23,"introduction":24,"targets":25,"mice":18,"pic":26},8,"Neuroscience","Neurological disorders impact one of the world's largest patient populations. Biocytogen's human antibody library offers broad coverage of neural targets and BBB-shuttle molecules, streamlining development from target validation to molecular design.","\u003Cp>Neurological disorders impact one of the world's largest patient populations. Biocytogen's human antibody library offers broad coverage of neural targets and BBB-shuttle molecules, streamlining development from target validation to molecular design.\u003C\u002Fp>","LY6G6D","https:\u002F\u002Fbiocytogen-no2.oss-cn-beijing.aliyuncs.com\u002F20251204\u002Farea-top-img8_1764825363512.png",{"id":28,"therapeuticArea":29,"description":30,"introduction":31,"targets":32,"mice":33,"pic":34},10,"Rare Diseases","Rare diseases are increasingly recognized as a critical area for targeted therapeutic innovation. Biocytogen's human antibody library provides diverse antibodies to accelerate rare disease therapy development. One example is BCG009, an anti-IGF-1R antibody with strong potential in the treatment of thyroid eye disease (TED).","\u003Cp>Rare diseases are increasingly recognized as a critical area for targeted therapeutic innovation. Biocytogen's human antibody library provides diverse antibodies to accelerate rare disease therapy development. One example is BCG009, an anti-IGF-1R antibody with strong potential in the treatment of thyroid eye disease (TED).\u003C\u002Fp>","CDH6,LY6G6D","","https:\u002F\u002Fbiocytogen-no2.oss-cn-beijing.aliyuncs.com\u002F20251204\u002Farea-top-img10_1764825601707.png"]